These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11270348)

  • 1. [Controversy: systemic amniocentesis for women 38 years and more? Is it not premature to no longer accept performing amniocentesis on a patient age 38 years or more?].
    Sagot P
    Gynecol Obstet Fertil; 2000 Oct; 28(10):769-71. PubMed ID: 11270348
    [No Abstract]   [Full Text] [Related]  

  • 2. [Controversy: systemic amniocentesis for women 38 years and more? Is it still lawful to recommend amniocentesis with the sole criterion being maternal age of 38 years or more?].
    Bernard JP
    Gynecol Obstet Fertil; 2000 Oct; 28(10):765-9. PubMed ID: 11244641
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prenatal cytogenetic diagnosis in the 2d trimester in older pregnant women].
    Subrt I; Benesová O; Stirská K; Zwinger A
    Cesk Gynekol; 1989 Nov; 54(9):677-80. PubMed ID: 2533885
    [No Abstract]   [Full Text] [Related]  

  • 4. Antenatal diagnosis of cytogenetic abnormalities.
    Simpson JL
    Semin Perinatol; 1980 Jul; 4(3):165-78. PubMed ID: 6447915
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of genetic counseling on decisions of pregnant women aged 35 years or over regarding amniocentesis in Turkey.
    Ilgin-Ruhi H; Yürür-Kutlay N; Tükün A; Bökesoy I
    Eur J Med Genet; 2005; 48(1):13-9. PubMed ID: 15953401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chromosome abnormalities: known risk factors].
    Ayme S; Mattei JF; Mattei MG; Giraud F
    J Genet Hum; 1980 Sep; 28(3):155-78. PubMed ID: 6450823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recourse to amniocentesis after the age of 38. Factors related to access to medical care].
    Czernichow P; Moirot H; Pierre M; Daniel P; Hemet J
    J Gynecol Obstet Biol Reprod (Paris); 1987; 16(6):729-36. PubMed ID: 2968393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of a Down syndrome live birth in women 45 years of age and older.
    Morris JK; De Vigan C; Mutton DE; Alberman E
    Prenat Diagn; 2005 Apr; 25(4):275-8. PubMed ID: 15849789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method of risk assessment affects acceptance rate of amniocentesis.
    de la Vega A; Verdiales M; Leavitt G
    P R Health Sci J; 2002 Sep; 21(3):233-5. PubMed ID: 12243114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors in a woman's decision to undergo genetic amniocentesis for advanced maternal age.
    Davies BL; Doran TA
    Nurs Res; 1982; 31(1):56-9. PubMed ID: 6214766
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of the third trimester amniocentesis for fetal karyotyping in women with fear of pregnancy loss].
    Picone O; Fuchs F; Sénat MV; Brisset S; Tachdjian G; Audibert F; Fernandez H; Frydman R
    J Gynecol Obstet Biol Reprod (Paris); 2008 Jun; 37(4):385-91. PubMed ID: 18191913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It could be you. Antenatal screening ... just another lottery?
    Rogers J
    Nurs Times; 1997 Feb 5-11; 93(6):54-5. PubMed ID: 9095934
    [No Abstract]   [Full Text] [Related]  

  • 13. Fear of pregnancy loss and fetal karyotyping: a place for third-trimester amniocentesis?
    Picone O; Senat MV; Rosenblatt J; Audibert F; Tachdjian G; Frydman R
    Fetal Diagn Ther; 2008; 23(1):30-5. PubMed ID: 17934295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Down syndrome.
    Lancet; 1987 Nov; 2(8567):1083-4. PubMed ID: 2444843
    [No Abstract]   [Full Text] [Related]  

  • 15. Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping.
    Cederholm M; Haglund B; Axelsson O
    BJOG; 2005 Apr; 112(4):394-402. PubMed ID: 15777434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers.
    Muller F; Thibaud D; Poloce F; Gelineau MC; Bernard M; Brochet C; Millet C; Réal JY; Dommergues M
    Prenat Diagn; 2002 Nov; 22(11):1036-9. PubMed ID: 12424771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the decision regarding amniocentesis in women at genetic risk because of age 35 years or older.
    Vergani P; Locatelli A; Biffi A; Ciriello E; Zagarella A; Pezzullo JC; Ghidini A
    Prenat Diagn; 2002 Sep; 22(9):769-74. PubMed ID: 12224068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of models of maternal age-specific risk for Down syndrome live births.
    Morris JK; Wald NJ; Mutton DE; Alberman E
    Prenat Diagn; 2003 Mar; 23(3):252-8. PubMed ID: 12627430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuchal translucency screening: how do women actually utilize the results?
    Caughey AB; Musci TJ; Belluomini J; Main D; Otto C; Goldberg J
    Prenat Diagn; 2007 Feb; 27(2):119-23. PubMed ID: 17152116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of amniocentesis.
    Lancet; 1986 Jul; 2(8500):225-6. PubMed ID: 2873473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.